Daklinza and Sovaldi to Treat Hep C Genotype 1
Share
Follow Us
The Editors at Hepatitis Central
February 11, 2016
Find out the details of the updated drug label.
FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hepatitis C Genotype 1
February 10, 2016
The U.S. Food and Drug Administration (FDA) has expanded the approved uses of the combination hepatitis C virus (HCV) regimen of Bristol-Myers Squibb’s (BMS) Daklinza (daclatasvir) and Gilead Sciences’ Sovaldi (sofosbuvir). Approved to treat genotype 3 of the virus in July 2015, the regimen may now treat genotype 1, as well as individuals with advanced cirrhosis and people whose hep C has returned after a liver transplant.
Continue reading this entire article:
http://www.aidsmeds.com/articles/Daklinza_Sovaldi_1667_28349.shtml
Comments are closed here.